The effects of a Baltimore factory mix-up on New Jersey’s supply of Johnson & Johnson’s one-dose COVID-19 vaccine are “to be determined,” Gov. Phil Murphy said Thursday.
“It doesn’t help it though,” the governor said during a press gaggle following an unrelated event. “We know our numbers this week and next week, on the J&J side, are up, next week in particular, meaningfully, but the signals we’re getting from the White House is the J&J number will go down then for at least the next couple weeks after that.”
It’s not clear, Murphy said, whether the coming slump is related to manufacturing errors at a Baltimore facility run by Emergent BioSolutions, which was subcontracted to manufacture doses of the Johnson & Johnson and AstraZeneca vaccines.
The manufacturing snafu, which federal officials reportedly believe was caused by human error, comes after lawmakers in New Jersey touted the single-dose vaccine.
Unlike inoculants manufactured by Pfizer and Moderna that have also won an emergency use authorization from the Food and Drug Administration, the one-dose Johnson & Johnson shot provides health officials with an easy method of vaccinating otherwise hard-to-reach residents, like the homebound and elderly or those in urban centers where vaccinations have lagged.
Health Commissioner Judy Persichilli on Wednesday said the state received 51,700 doses of the Johnson & Johnson vaccine this week, with next week’s delivery expected to rise to 131,600. It’s not clear how much smaller shipments will be in the two following weeks.